Adherence to Oral Anticancer Treatment Using Electronic Monitoring System
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Other: Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System "
- Registration Number
- NCT01058044
- Lead Sponsor
- Centre Jean Perrin
- Brief Summary
The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Age > 18 years
- histologically proven malignant tumor
- documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor
- ambulatory treated subject
- Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
- Written informed consent
Exclusion Criteria
- any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
- patient who does not agreed to participate the program
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description adherence assessment group Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System " evaluation of adherence using MEMS
- Primary Outcome Measures
Name Time Method evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. everey visit during 6 months
- Secondary Outcome Measures
Name Time Method evaluation of liberal nurse satisfaction inclusion resort to healthcare system (oncologist, doctor, nurse, hospital pharmacy, dispensary pharmacy) during 6 months Patient satisfaction 6 months drug interaction during 6 months
Trial Locations
- Locations (1)
Centre Jean Perrin
🇫🇷Clermont-Ferrand, France